Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Susanne Brandstetter
Observed name:
Brandstetter, Susanne
Institutions:
University Hospital Regensburg,
Krankenhaus Barmherzige Brüder,
University of Regensburg
Observed institutions:
Merck KGaA, Darmstadt (Germany),
University Hospital Regensburg,
Krankenhaus Barmherzige Brüder,
Merck Healthcare KGaA, Darmstadt (Germany),
University of Regensburg
ORCID:
0009-0001-3038-3503
Observed ORCID:
0009-0001-3038-3503
OpenAlex ID:
A5093480254
M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2023
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
·
Cancer Immunology Research
·
7
Deriving acceptable limits for non-mutagenic impurities in medicinal products – Durational adjustments
2024
·
Michelle O. Kenyon
, Matthew Martin
, et al.
·
Regulatory Toxicology and Pharmacology
·
6
Food Allergy Diagnosis in Early Childhood: Journey Mapping Study With Parents and Pediatricians
2026
·
Madlen Hörold
, Magdalena Rohr
, et al.
·
Clinical and Translational Allergy
·
1
PDF
Prävention und Prädiktion von Nahrungsmittelallergien auf Instagram: eine systematische Evaluation
2026
·
Maja Beyer
, Martina Hasseler
, et al.
·
Das Gesundheitswesen
HELICAP - Allergy Journey Study
2026
·
Magdalena Rohr
, Susanne Brandstetter
, et al.
·
OSF Preprints (OSF Preprints)
Risikoprädiktion und Prävention von Nahrungsmittelallergien bei Kindern: eine qualitative Studie zur Elternperspektive
2025
·
Magdalena Rohr
, Katharina Gerhardinger
, et al.
·
Monatsschrift Kinderheilkunde
PDF
Mütter mit Migrationshintergrund kennen Unterstützungsangebote vor und nach der Geburt signifikant weniger als Mütter ohne Migrationshintergrund: querschnittliche Erhebung in zwei Geburtskliniken
2025
·
Benedikt Selbertinger
, David Rothfuß
, et al.
·
Das Gesundheitswesen
Connecting the salivary microbiome and blood epigenome with a machine learning interaction approach in children with moderate-to-severe asthma
2024
·
Jelle M. Blankestijn
, Mario Martin-Almeida
, et al.
·
European Respiratory Journal
Data from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S4 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S14 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S13 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S13 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S3 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S5 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S2 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S11 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S12 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S10 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S8 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Supplementary Tables from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S9 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S7 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S9 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Figure S1 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024
·
Chunxiao Xu
, Xueyuan Zhou
, et al.
Show more works
View as search
Works count:
34
Citation count:
14
H-index:
2
I10-index:
Year
Topic
Type